Written answers
Wednesday, 27 September 2017
Department of Health
Medicinal Products Licensing
Róisín Shortall (Dublin North West, Social Democrats)
Link to this: Individually | In context | Oireachtas source
145. To ask the Minister for Health further to Parliamentary Question No. 535 of 20 September 2017, if his attention has been drawn to the impact that the changes of the prescribing of Lidocaine have had on persons with fibromyalgia; if the HSE medicines management programme has investigated the impact that changes to the prescription of pain medication has on persons with fibromyalgia; and if he will make a statement on the matter. [40839/17]
Simon Harris (Wicklow, Fine Gael)
Link to this: Individually | In context | Oireachtas source
Under the Health (Pricing and Supply of Medical Goods) Act 2013, the HSE has statutory responsibility for the administration of the community drug schemes; therefore, the matter has been referred to the HSE for attention and direct reply to the Deputy.
No comments